Terms: = Ovarian cancer AND ATR, Q13535, 545, ENSG00000175054, MEC1, SCKL, SCKL1, FRP1 AND Prognosis
18 results:
1. Selectively targeting BCL6 using a small molecule inhibitor is a potential therapeutic strategy for ovarian cancer.
Wu M; Xie J; Xing Y; Zhang L; Chen H; Tang B; Zhou M; Lv S; Huang D; Jian S; Zhou C; Liu M; Guo W; Chen Y; Yi Z
Int J Biol Sci; 2024; 20(2):486-501. PubMed ID: 38169532
[TBL] [Abstract] [Full Text] [Related]
2. Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8
Heinze K; Nazeran TM; Lee S; Krämer P; Cairns ES; Chiu DS; Leung SC; Kang EY; Meagher NS; Kennedy CJ; Boros J; Kommoss F; Vollert HW; Heitz F; du Bois A; Harter P; Grube M; Kraemer B; Staebler A; Kommoss FK; Heublein S; Sinn HP; Singh N; Laslavic A; Elishaev E; Olawaiye A; Moysich K; Modugno F; Sharma R; Brand AH; Harnett PR; DeFazio A; Fortner RT; Lubinski J; Lener M; Tołoczko-Grabarek A; Cybulski C; Gronwald H; Gronwald J; Coulson P; El-Bahrawy MA; Jones ME; Schoemaker MJ; Swerdlow AJ; Gorringe KL; Campbell I; Cook L; Gayther SA; Carney ME; Shvetsov YB; Hernandez BY; Wilkens LR; Goodman MT; Mateoiu C; Linder A; Sundfeldt K; Kelemen LE; Gentry-Maharaj A; Widschwendter M; Menon U; Bolton KL; Alsop J; Shah M; Jimenez-Linan M; Pharoah PD; Brenton JD; Cushing-Haugen KL; Harris HR; Doherty JA; Gilks B; Ghatage P; Huntsman DG; Nelson GS; Tinker AV; Lee CH; Goode EL; Nelson BH; Ramus SJ; Kommoss S; Talhouk A; Köbel M; Anglesio MS
J Pathol; 2022 Apr; 256(4):388-401. PubMed ID: 34897700
[TBL] [Abstract] [Full Text] [Related]
3. Genomic mutation features identify distinct BRCA-associated mutation characteristics in endometrioid carcinoma and endometrioid ovarian carcinoma.
Cao C; Yu R; Gong W; Liu D; Zhang X; Fang Y; Xia Y; Zhang W; Gao Q
Aging (Albany NY); 2021 Nov; 13(22):24686-24709. PubMed ID: 34837690
[TBL] [Abstract] [Full Text] [Related]
4. Co-regulation and function of
Barger CJ; Chee L; Albahrani M; Munoz-Trujillo C; Boghean L; Branick C; Odunsi K; Drapkin R; Zou L; Karpf AR
Elife; 2021 Apr; 10():. PubMed ID: 33890574
[TBL] [Abstract] [Full Text] [Related]
5. MicroRNA-545 suppresses progression of ovarian cancer through mediating PLK1 expression by a direct binding and an indirect regulation involving KDM4B-mediated demethylation.
Zhang H; Zhang K; Xu Z; Chen Z; Wang Q; Wang C; Cui J
BMC Cancer; 2021 Feb; 21(1):163. PubMed ID: 33588776
[TBL] [Abstract] [Full Text] [Related]
6. Participation of the atr/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer.
Gralewska P; Gajek A; Marczak A; Rogalska A
J Hematol Oncol; 2020 Apr; 13(1):39. PubMed ID: 32316968
[TBL] [Abstract] [Full Text] [Related]
7. Targeting Ku86 enhances X-ray-induced radiotherapy sensitivity in serous ovarian cancer cells.
Ma Q; Kai J; Liu Y; Tong Y; Xie S; Zheng H; Wang Y; Guo L; Lu R
Int J Biochem Cell Biol; 2020 Apr; 121():105705. PubMed ID: 32027982
[TBL] [Abstract] [Full Text] [Related]
8. Targeting the High-Mobility Group Box 3 Protein Sensitizes Chemoresistant ovarian cancer Cells to Cisplatin.
Mukherjee A; Huynh V; Gaines K; Reh WA; Vasquez KM
Cancer Res; 2019 Jul; 79(13):3185-3191. PubMed ID: 31061066
[TBL] [Abstract] [Full Text] [Related]
9. Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress.
Bayard Q; Meunier L; Peneau C; Renault V; Shinde J; Nault JC; Mami I; Couchy G; Amaddeo G; Tubacher E; Bacq D; Meyer V; La Bella T; Debaillon-Vesque A; Bioulac-Sage P; Seror O; Blanc JF; Calderaro J; Deleuze JF; Imbeaud S; Zucman-Rossi J; Letouzé E
Nat Commun; 2018 Dec; 9(1):5235. PubMed ID: 30531861
[TBL] [Abstract] [Full Text] [Related]
10. DUOXA1-mediated ROS production promotes cisplatin resistance by activating atr-Chk1 pathway in ovarian cancer.
Meng Y; Chen CW; Yung MMH; Sun W; Sun J; Li Z; Li J; Li Z; Zhou W; Liu SS; Cheung ANY; Ngan HYS; Braisted JC; Kai Y; Peng W; Tzatsos A; Li Y; Dai Z; Zheng W; Chan DW; Zhu W
Cancer Lett; 2018 Aug; 428():104-116. PubMed ID: 29704517
[TBL] [Abstract] [Full Text] [Related]
11. Impact of Conservative Managements in Young Women With Grade 2 or 3 Endometrial Adenocarcinoma Confined to the Endometrium.
Gonthier C; Trefoux-Bourdet A; Koskas M
Int J Gynecol Cancer; 2017 Mar; 27(3):493-499. PubMed ID: 28187090
[TBL] [Abstract] [Full Text] [Related]
12. The impact of DNA damage response gene polymorphisms on therapeutic outcomes in late stage ovarian cancer.
Guffanti F; Fruscio R; Rulli E; Damia G
Sci Rep; 2016 Dec; 6():38142. PubMed ID: 27905519
[TBL] [Abstract] [Full Text] [Related]
13. [Expressions of CD133, E-cadherin, and Snail in epithelial ovarian cancer and their clinicopathologic and prognostic implications].
Yu L; Zhou L; Wu S; Song W; Cheng Z; Guo B
Nan Fang Yi Ke Da Xue Xue Bao; 2015 Aug; 35(9):1297-302. PubMed ID: 26403742
[TBL] [Abstract] [Full Text] [Related]
14. Long-term follow-up of patients with an isolated ovarian recurrence after conservative treatment of epithelial ovarian cancer: review of the results of an international multicenter study comprising 545 patients.
Bentivegna E; Fruscio R; Roussin S; Ceppi L; Satoh T; Kajiyama H; Uzan C; Colombo N; Gouy S; Morice P
Fertil Steril; 2015 Nov; 104(5):1319-24. PubMed ID: 26149354
[TBL] [Abstract] [Full Text] [Related]
15. Ataxia-Telangiectasia and RAD3-Related and Ataxia-Telangiectasia-Mutated Proteins in Epithelial ovarian Carcinoma: Their Expression and Clinical Significance.
Lee B; Lee HJ; Cho HY; Suh DH; Kim K; No JH; Kim H; Kim YB
Anticancer Res; 2015 Jul; 35(7):3909-16. PubMed ID: 26124337
[TBL] [Abstract] [Full Text] [Related]
16. The BRCA1/2-directed miRNA signature predicts a good prognosis in ovarian cancer patients with wild-type BRCA1/2.
Gu Y; Zhang M; Peng F; Fang L; Zhang Y; Liang H; Zhou W; Ao L; Guo Z
Oncotarget; 2015 Feb; 6(4):2397-406. PubMed ID: 25537514
[TBL] [Abstract] [Full Text] [Related]
17. Overexpression of catalytic subunit M2 in patients with ovarian cancer.
Wang LM; Lu FF; Zhang SY; Yao RY; Xing XM; Wei ZM
Chin Med J (Engl); 2012 Jun; 125(12):2151-6. PubMed ID: 22884145
[TBL] [Abstract] [Full Text] [Related]
18. RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells.
Arora S; Bisanz KM; Peralta LA; Basu GD; Choudhary A; Tibes R; Azorsa DO
Gynecol Oncol; 2010 Sep; 118(3):220-7. PubMed ID: 20722101
[TBL] [Abstract] [Full Text] [Related]
